Chinese biopharmaceutical company: KYLO-11 "LPA SIRNA" phase II clinical trial completed with the enrollment of the first patient in the United States.

Chinese biopharmaceutical company announced that its wholly-owned subsidiary, Hangzhou Hecia Biopharmaceutical Co., Ltd., has completed the enrollment of the first patient in the United States for the Phase II clinical trial of the innovative drug Kylo-11 "LPA siRNA" developed independently by the company. This drug targets atherosclerotic cardiovascular disease with elevated lipoprotein and the Chinese part of the clinical trial had enrolled the first patient in October 2025.